Testing a new dengue vaccine for safety and effectiveness in Bangladesh.
A Phase II Evaluation of the Safety and Protective Efficacy of the Live Attenuated Tetravalent Dengue Vaccine TetraVax-DV with Challenge by the Recombinant DENV-2 Virus in a Dengue Endemic Population
This study is testing a new dengue vaccine called TV005 to see how well it protects adults in Bangladesh from getting dengue, and it's looking for healthy volunteers to help find out if the vaccine works for everyone, whether they've had dengue before or not.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Vermont & St Agric College NIH-funded |
| Lab location | 1 site (Burlington, United States) |
| Project ID | NIH-10890023 on NIH RePORTER |
What this research studies
This research investigates the safety and protective efficacy of a new tetravalent dengue vaccine called TV005 in adults living in dengue-endemic areas of Bangladesh. Participants will receive the vaccine and then be exposed to a controlled challenge with the dengue virus to assess how well the vaccine protects against infection. The study aims to enroll 224 healthy adult volunteers, both those who have been previously exposed to dengue and those who have not, to ensure a comprehensive evaluation of the vaccine's effectiveness. The results will help determine if this vaccine can be a viable option for preventing dengue in high-risk populations.
Who could benefit from this research
Good fit: Ideal candidates for participation are healthy adults aged 18 and older living in dengue-endemic areas, particularly in Bangladesh.
Not a fit: Patients who are not adults or those living outside of dengue-endemic regions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a safe and effective vaccine that significantly reduces the incidence of dengue fever in endemic regions.
How similar studies have performed: Previous studies have shown that similar vaccine-challenge approaches have been successful in evaluating dengue vaccines in other populations.
Where this research is happening
Burlington, United States
- University of Vermont & St Agric College — Burlington, United States (Active)
Researchers
- Principal investigator: Kirkpatrick, Beth Diane — University of Vermont & St Agric College
- Study coordinator: Kirkpatrick, Beth Diane
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.